---
title: "BullFrog AI Enters One-Year Feasibility Pact With Global Pharma to Advance MDD Targets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281082557.md"
description: "BullFrog AI has signed a one-year Feasibility Agreement with an undisclosed global pharmaceutical company to utilize its bfLEAP platform for identifying drug targets for major depressive disorder (MDD). The agreement includes milestone payments for deliverables such as prioritized targets and causal gene networks. The client may secure exclusive rights to a final target for three years and can terminate the agreement with 30 days' notice. The agreement was effective from March 27, 2026, as per the SEC filing."
datetime: "2026-03-30T22:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281082557.md)
  - [en](https://longbridge.com/en/news/281082557.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281082557.md)
---

# BullFrog AI Enters One-Year Feasibility Pact With Global Pharma to Advance MDD Targets

BullFrog AI entered into a Feasibility Agreement with an undisclosed global pharmaceutical company to apply its bfLEAP platform to identify and prioritize drug targets for major depressive disorder. The one-year engagement includes milestone payments tied to deliverables such as prioritized targets, causal gene networks, and target dossiers. The client may obtain an exclusive right to use a selected final target for three years and can terminate without cause on 30 days’ notice; standard breach remedies apply.

**Agreement details:**

-   **Agreement type**: Feasibility Agreement for AI-driven drug target discovery (MDD)
-   **Counterparty**: Undisclosed Global Pharmaceutical Company
-   **Signed / Effective**: Mar 27 2026 / same
-   **Duration / Termination**: 1 year
-   **Reason**: Apply bfLEAP to identify MDD drug targets

Original SEC Filing: BullFrog AI Holdings, Inc. \[ BFRG \] - 8-K - Mar. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [BFRGW.US](https://longbridge.com/en/quote/BFRGW.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BFRG.US](https://longbridge.com/en/quote/BFRG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)